A clinical trial developed by a Taiwanese research team has offered a glimmer of hope for patients of neuroblastoma, a malignant cancer that appears in early childhood, a press statement released by the Academia Sinica said.
The research team at the research institute has proven that a combination of anti-cancer monoclonal antibodies (mAbs) with cytokines (natural hormones that help the immune system) is an effective anti-cancer therapy.
The new immunotherapy treatment pioneered by the research team, headed by Alice Yu (陳鈴津), deputy director of Academia Sinica’s Genomics Research Center, is the first study that confirms that immunotherapy is effective in improving cure rates for this childhood cancer, the statement said.
Yu, a pediatrician, has been working on the therapy for more than 20 years. She completed the Phase I and Phase II trials of this antibody at the University of California in San Diego.
The latest Phase III trial was sponsored by the US-based Children’s Oncology Group (COG), a cancer research organization, and the National Cancer Institute of the National Institutes of Health in the US. The latest results included children with neuroblastoma from many parts of the world.
Neuroblastoma is a malignant cancer occurring in early childhood in which the cancer cells arise from the nerve cells in the neck, chest or abdomen.
It is the most common cancer diagnosed in the first year of life and is responsible for 15 percent of cancer-related deaths in children.
The Phase III study showed that children with high risk neuroblastoma who received the new antibody-based immunotherapy (chimeric anti-GD2 antibody ch14.18) have a 20 percent better chance of living free of cancer, a significantly improved cure rate.
So far, Yu said, all US Federal Drug Administration (FDA) approved therapeutic anti-cancer mAbs or vaccines are directed against protein or glycoprotein antigens.
“The Phase III clinical trial is the first mAb targeting a glycolipid that has been shown to be effective,” Yu said.
More importantly, she added, this is the first study that proves that immunotherapy is effective in improving cure rates for this childhood cancer and her team is now focusing on making sure immunotherapy can be available to all children with this disease and on improving results.
COG Chairman Gregory Reaman stated in a press release that the clinical benefit of this approach against the notoriously stubborn child cancer is extraordinary and that the COG is anxious to continue its investigation to better define the toxicities and confirm its satisfactory risk-benefit ratio.
“We are hopeful that that this further study will result in commercialization and FDA approval and licensing of this experimental immunotherapeutic agent so that it can be made readily available as standard therapy to all children with this dreaded disease,” Reaman said in the statement.
Conventional treatment for the disease includes surgery, intensive chemotherapy with stem cell rescue (in which patients’ stem cells removed before treatment are returned after chemotherapy to repopulate the blood and immune system) and radiation therapy.
Despite these aggressive measures, only 30 percent of patients survive.
The immunotherapy evaluated in this study targets a specific glycolipid (sugar and fat) molecule on neuroblastoma cells called GD2 — which inhibits the immune system from attacking cancer cells — with an antibody called ch14.18.
This antibody binds to GD2 and provokes an attack by different types of immune cells against the cancer.
In her study, Yu and her colleagues compared the two-year event-free survival rate (the ratio of patients who were still alive and did not experience a recurrence) of 113 neuroblastoma patients who received the standard treatment (retinoic acid) plus the newly developed immunotherapy with 113 similar patients who only received the standard treatment.
The event-free survival rate for the immunotherapy group was 66 percent, compared to 46 percent for the standard treatment group. The most common side effects in the immunotherapy group were pain, vascular leak syndrome and allergic reactions.
As the study is the first effective immunotherapy reported for the disease and the first improvement on neuroblastoma cure rates of the last 10 years, it has drawn worldwide attention and was reported in USA Today and by US television network CBS.
It is estimated that it will take at least another two years to get FDA approval for the therapy.
Taipei has once again made it to the top 100 in Oxford Economics’ Global Cities Index 2025 report, moving up five places from last year to 60. The annual index, which was published last month, evaluated 1,000 of the most populated metropolises based on five indices — economics, human capital, quality of life, environment and governance. New York maintained its top spot this year, placing first in the economics index thanks to the strength of its vibrant financial industry and economic stability. Taipei ranked 263rd in economics, 44th in human capital, 15th in quality of life, 284th for environment and 75th in governance,
The Sports Administration yesterday demanded an apology from the national table tennis association for barring 17-year-old Yeh Yi-tian (葉伊恬) from competing in the upcoming World Table Tennis (WTT) United States Smash tournament in Las Vegas this July. The sports agency said in a statement that the Chinese Taipei Table Tennis Association (CTTTA) must explain to the public why it withdrew Yeh from the WTT tournament in Las Vegas. The sports agency said it contacted the association to express its disapproval of the decision-making process after receiving a complaint from Yeh’s coach, Chuang
Control Yuan Secretary-General Lee Chun-yi (李俊俋) tendered his resignation last night, admitting that he had misused a government vehicle, as reported by media. His resignation was immediately accepted by the Control Yuan. In a statement explaining why he had resigned, Lee apologized for using a Control Yuan vehicle to transport his dog to a pet grooming salon on May 20. The issue first came to light late last month, when TVBS News reported that Lee had instructed his driver to take the dog to the salon. The news channel broadcast photos that it said were taken by an unnamed whistle-blower, which purportedly showed the
A former officer in China’s People’s Liberation Army (PLA) who witnessed the aftermath of the 1989 Tiananmen Square massacre has warned that Taiwan could face a similar fate if China attempts to unify the country by force. Li Xiaoming (李曉明), who was deployed to Beijing as a junior officer during the crackdown, said Taiwanese people should study the massacre carefully, because it offers a glimpse of what Beijing is willing to do to suppress dissent. “What happened in Tiananmen Square could happen in Taiwan too,” Li told CNA in a May 22 interview, ahead of the massacre’s 36th anniversary. “If Taiwanese students or
RSS